Georgia is currently home to 1948 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Atlanta, Augusta, Decatur and Savannah. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
NCT05476770
Recruiting
Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine the safety of this novel agent in pediatric patients with relapsed/refractory hematologic malignancies. The mechanism by which tagraxofusp kills cells is distinct from that of conventional chemotherapy. Tagraxofusp directly targets CD123 that is pre... Read More
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
12/04/2024
Locations: Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia
Conditions: Hematologic Malignancy, AML, ALL, BPDCN, MDS, Lymphoblastic Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia
Register for Updates
AngelMed Guardian® System PMA Post Approval Study
NCT05412927
Recruiting
500 Patients (minimum) will be enrolled following commercial implant. Will be treated by their physicians using the standard of care. Standard of care for the Guardian includes an in-office initial programming visit 7-14 days following implant and every 6 months.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
12/04/2024
Locations: Northside Hospital Cardiovascular Institute, Atlanta, Georgia
Conditions: Acute Coronary Syndrome
Register for Updates
Dose Response Effects of Pecan Consumption
NCT05949879
Recruiting
The bioactive compounds contained in tree nuts have been shown to beneficially affect cardiometabolic health outcomes. Pecans contain more total phenols, sterols, and flavonoids than any other tree nut. They also are a rich source of polyunsaturated fatty acids (PUFAs), fiber, vitamin A, vitamin E, folic acid, calcium, magnesium, phosphorus, potassium, and zinc. These bioactive components in pecans are likely the reason for the previously documented improvements in cardiometabolic health. The s... Read More
Gender:
ALL
Ages:
Between 30 years and 75 years
Trial Updated:
12/03/2024
Locations: University of Georgia, Athens, Georgia
Conditions: Dyslipidemias, Overweight and Obesity, Nutrition, Healthy
Register for Updates
A Research Study of Abdominal Ultrasound (FAST) in Children With Blunt Torso Trauma
NCT05910567
Recruiting
Bleeding from intra-abdominal injuries is a leading cause of traumatic deaths in children. Abdominal CT is the reference standard test for diagnosing intra-abdominal injuries. Compelling reasons exist, however, to both aggressively evaluate injured children for intra-abdominal injuries with CT and to limit abdominal CT evaluation to solely those at non-negligible risk. The focused assessment sonography for trauma (FAST) examination can help focus patient evaluation in just this manner by potenti... Read More
Gender:
ALL
Ages:
17 years and below
Trial Updated:
12/03/2024
Locations: Emory University Children's Healthcare of Atlanta, Atlanta, Georgia
Conditions: Blunt Trauma to Abdomen, Wounds and Injuries, Abdomen Injury, Abdominal Injury, Abdomen, Acute
Register for Updates
Hyrax Vs. Invisalign Palatal Expander Clinical Study
NCT06662279
Recruiting
The purpose of this study is to compare expansion result and the overall experience between the Invisalign Palatal Expander and the Hyrax expander.
Gender:
ALL
Ages:
Between 6 years and 11 years
Trial Updated:
12/02/2024
Locations: Spillers Orthodontics, Warner Robins, Georgia
Conditions: Malocclusions, Narrow Maxilla, Narrow Maxillary Arch, Crowding
Register for Updates
HIV/STD Risk and PrEP Implementation Messaging Among Gay, Bisexual, and Other Men Who Have Sex with Men
NCT06183502
Recruiting
The goal of this observational study is to learn about awareness around PrEP use and adherence, condom use, sexual risk-taking behavior, and substance-using behaviors in men having sex with men. The main objective is to study a prospective cohort of MSM in Atlanta, Chicago, and San Diego to understand men's strategies to prevent HIV/Sexually Transmissible Infections (STIs), including PrEP use and adherence, condom use, sexual risk-taking behavior, and substance-using behaviors Participants will... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
11/25/2024
Locations: Emory University, Atlanta, Georgia
Conditions: Sexually Transmitted Infections, Gay, Pre Exposure Prophylaxis
Register for Updates
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
NCT03860883
Recruiting
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with stage II primary invasive cutaneous melanomas (AJCC 8th edition) to determine differences in disease-free survival. A reduction in margins is expected to improve patient quality of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/25/2024
Locations: Emory University Hospital Midtown, Atlanta, Georgia
Conditions: Cutaneous Melanoma, Stage II
Register for Updates
ProACT Post-Approval Study
NCT03767595
Recruiting
The ProACT Post Approval Study is a 5-year prospective, open-label, multi-center study designed to evaluate the long-term incidence of urethral stricture and device erosion after ProACT implantation. In addition, the study will evaluate whether treatment with ProACT affects clinical outcomes after subsequent SUI therapies.
Gender:
MALE
Ages:
50 years and above
Trial Updated:
11/25/2024
Locations: Emory University, Atlanta, Georgia
Conditions: Stress Urinary Incontinence
Register for Updates
Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease
NCT03304821
Recruiting
Peripheral artery disease (PAD) is a disease in which plaque builds up in the arteries that carry blood to the head, organs, and limbs. PAD usually occurs in the arteries in the legs, but can affect any arteries. Over time, plaque can harden and narrow the arteries which limits the flow of oxygen-rich blood to organs and other parts of the body. Blocked blood flow to the arteries can cause pain and numbness. The pain is usually worse with exercise and gets better with rest. PAD can raise the ris... Read More
Gender:
ALL
Ages:
Between 21 years and 85 years
Trial Updated:
11/25/2024
Locations: Emory University Hospital, Atlanta, Georgia
Conditions: Peripheral Artery Disease (PAD)
Register for Updates
A Smoke-Free Home Intervention in Tribal Communities
NCT06583148
Recruiting
This clinical trial evaluates a smoke-free home intervention for reducing exposure to secondhand smoke from commercial tobacco in homes of participants who live in rural tribal communities. Smoke-free homes are an innovative and relatively untapped strategy for cancer prevention in rural tribal communities. Smoke-free policies, including those that target homes, can reduce exposure to secondhand smoke and support smoking cessation. Rural and racial/ethnic inequities intersect to increase tobacco... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/22/2024
Locations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Conditions: Tobacco-Related Carcinoma
Register for Updates
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC
NCT06263543
Recruiting
The purpose of this research study is to see if the medication sacituzumab govitecan (SG) is effective at the currently approved dose and schedule in people who have previously received trastuzumab deruxtecan (T-DXd) for the treatment of metastatic, hormone receptor positive (HR+)/human epidermal growth factor 2 low (HER2 low) breast cancer. Although SG is approved to treat metastatic HR+/HER2 negative breast cancer, the aim of this study is to determine if SG is still effective specifically in... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2024
Locations: Winship Cancer Institute at Emory University, Atlanta, Georgia
Conditions: Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Low Breast Cancer
Register for Updates
Study of SX-682 Alone and in Combination with Oral or Intravenous Decitabine in Subjects with Myelodysplastic Syndrome
NCT04245397
Recruiting
This study will determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and recommended Phase 2 dose (RP2D) of SX-682 in the treatment of patients with Myelodysplastic Syndromes (MDS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2024
Locations: Emory University, Atlanta, Georgia
Conditions: Myelodysplastic Syndromes
Register for Updates